<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>16</Volume>
				<Issue>6</Issue>
				<PubDate PubStatus="epublish">
					<Year>2015</Year>
					<Month>06</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Association Between Alterations in the Serum 25-Hydroxyvitamin D Status During Follow-Up and Breast Cancer Patient Prognosis</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>2507</FirstPage>
			<LastPage>2513</LastPage>
			<ELocationID EIdType="pii">30765</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>&lt;b&gt;Background:&lt;/b&gt; Serum vitamin D status can affect the prognosis of breast cancer patients. Our aim was todetermine the association between alterations in the 25-hydroxyvitamin D [25(OH)D] status during follow-upand the prognosis of breast cancer patients. Additionally, we evaluated the association between the 25(OH)Dstatus at the time of diagnosis and the prognosis using a detailed age and stage categorization. Materials and&lt;br/&gt;&lt;b&gt;Methods&lt;/b&gt;: Four hundred and sixty-nine Korean breast cancer patients were included. We collected patientclinicopathological data, including their serum 25(OH)D concentration at diagnosis and at the annual followupuntil 4 years after diagnosis. The patients were divided according to their 25(OH)D status at diagnosis intoa deficient (&lt;20 ng/ml) and a non-deficient (≥20 ng/ml) group. At follow-up, patients were categorized into thefour following groups according to 25(OH)D status alterations: persistently deficient, improved, deterioratedand persistently non-deficient. &lt;br/&gt;&lt;b&gt;Results&lt;/b&gt;: At diagnosis, 118 patients were classified into the deficient group and 351into the non-deficient group. After a median follow-up period of 85.8±31.0 months, the patients with advancedstagedisease or an older age in the non-deficient group showed a significantly better survival compared with thedeficient group. Furthermore, at the 1-year follow-up of 25(OH)D status, the persistently non-deficient group andthe improved group had better survival compared with the other two groups. &lt;br/&gt;&lt;b&gt;Conclusions&lt;/b&gt;: Our results suggestthat maintaining an optimal 25(OH)D status at diagnosis and during the 1-year follow-up period is importantfor improving breast cancer patient survival.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">breast cancer</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">25-hydroxyvitamin D</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">follow-up</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">survival</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_30765_251691f9067ae74ae2282426f57f9905.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
